Hepatitis B vaccine - Chongqing Jiachen

Drug Profile

Hepatitis B vaccine - Chongqing Jiachen

Alternative Names: Epsilon-PA-44; PA-44

Latest Information Update: 23 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chongqing Jiachen Biotechnology
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 06 Jun 2012 Chongqing Jiachen Biotechnology completes enrolment in its Phase-II trial for Hepatitis B (combination therapy) in China (NCT01326546)
  • 30 Nov 2011 Chongqing Jiachen Biotechnology completes a phase II trial in Hepatitis B in China (NCT00869778)
  • 30 Jun 2010 Phase-II clinical trials in Hepatitis B (combination therapy) in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top